195 related articles for article (PubMed ID: 36618440)
1. Embryonic lethality and defective mammary gland development of activator-function impaired conditional knock-in
Senger K; Yuan W; Sagolla M; Doerr J; Bolon B; Ziai J; Sun KH; Warming S; Roose-Girma M; Zhang N; Tam L; Newman RJ; Chaudhuri S; Antony A; Goldstein LD; Durinck S; Jaiswal BS; Lafkas D; Modrusan Z; Seshagiri S
Adv Genet (Hoboken); 2021 Mar; 2(1):e10036. PubMed ID: 36618440
[TBL] [Abstract][Full Text] [Related]
2. Conditional loss of ErbB3 delays mammary gland hyperplasia induced by mutant PIK3CA without affecting mammary tumor latency, gene expression, or signaling.
Young CD; Pfefferle AD; Owens P; Kuba MG; Rexer BN; Balko JM; Sánchez V; Cheng H; Perou CM; Zhao JJ; Cook RS; Arteaga CL
Cancer Res; 2013 Jul; 73(13):4075-85. PubMed ID: 23633485
[TBL] [Abstract][Full Text] [Related]
3. ErbB3 is required for ductal morphogenesis in the mouse mammary gland.
Jackson-Fisher AJ; Bellinger G; Breindel JL; Tavassoli FA; Booth CJ; Duong JK; Stern DF
Breast Cancer Res; 2008; 10(6):R96. PubMed ID: 19019207
[TBL] [Abstract][Full Text] [Related]
4. The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium.
Balko JM; Miller TW; Morrison MM; Hutchinson K; Young C; Rinehart C; Sánchez V; Jee D; Polyak K; Prat A; Perou CM; Arteaga CL; Cook RS
Proc Natl Acad Sci U S A; 2012 Jan; 109(1):221-6. PubMed ID: 22178756
[TBL] [Abstract][Full Text] [Related]
5. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
Kim A; Liu B; Ordonez-Ercan D; Alvarez KM; Jones LD; McKimmey C; Edgerton SM; Yang X; Thor AD
Breast Cancer Res; 2005; 7(5):R708-18. PubMed ID: 16168116
[TBL] [Abstract][Full Text] [Related]
6. Uncoupling of PI3K from ErbB3 impairs mammary gland development but does not impact on ErbB2-induced mammary tumorigenesis.
Lahlou H; Müller T; Sanguin-Gendreau V; Birchmeier C; Muller WJ
Cancer Res; 2012 Jun; 72(12):3080-90. PubMed ID: 22665265
[TBL] [Abstract][Full Text] [Related]
7. Activated Akt1 accelerates MMTV-c-ErbB2 mammary tumourigenesis in mice without activation of ErbB3.
Young CD; Nolte EC; Lewis A; Serkova NJ; Anderson SM
Breast Cancer Res; 2008; 10(4):R70. PubMed ID: 18700973
[TBL] [Abstract][Full Text] [Related]
8. HER3 is required for HER2-induced preneoplastic changes to the breast epithelium and tumor formation.
Vaught DB; Stanford JC; Young C; Hicks DJ; Wheeler F; Rinehart C; Sánchez V; Koland J; Muller WJ; Arteaga CL; Cook RS
Cancer Res; 2012 May; 72(10):2672-82. PubMed ID: 22461506
[TBL] [Abstract][Full Text] [Related]
9. Changes in ErbB2 (her-2/neu), ErbB3, and ErbB4 during growth, differentiation, and apoptosis of normal rat mammary epithelial cells.
Darcy KM; Zangani D; Wohlhueter AL; Huang RY; Vaughan MM; Russell JA; Ip MM
J Histochem Cytochem; 2000 Jan; 48(1):63-80. PubMed ID: 10653587
[TBL] [Abstract][Full Text] [Related]
10. ErbB3 ablation impairs PI3K/Akt-dependent mammary tumorigenesis.
Cook RS; Garrett JT; Sánchez V; Stanford JC; Young C; Chakrabarty A; Rinehart C; Zhang Y; Wu Y; Greenberger L; Horak ID; Arteaga CL
Cancer Res; 2011 Jun; 71(11):3941-51. PubMed ID: 21482676
[TBL] [Abstract][Full Text] [Related]
11. The ErbB/HER family of protein-tyrosine kinases and cancer.
Roskoski R
Pharmacol Res; 2014 Jan; 79():34-74. PubMed ID: 24269963
[TBL] [Abstract][Full Text] [Related]
12. NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice.
Krane IM; Leder P
Oncogene; 1996 Apr; 12(8):1781-8. PubMed ID: 8622899
[TBL] [Abstract][Full Text] [Related]
13. ErbB3 (HER3) interaction with the p85 regulatory subunit of phosphoinositide 3-kinase.
Hellyer NJ; Cheng K; Koland JG
Biochem J; 1998 Aug; 333 ( Pt 3)(Pt 3):757-63. PubMed ID: 9677338
[TBL] [Abstract][Full Text] [Related]
14. ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation.
Shi F; Telesco SE; Liu Y; Radhakrishnan R; Lemmon MA
Proc Natl Acad Sci U S A; 2010 Apr; 107(17):7692-7. PubMed ID: 20351256
[TBL] [Abstract][Full Text] [Related]
15. Estrogenic promotion of ErbB2 tyrosine kinase activity in mammary tumor cells requires activation of ErbB3 signaling.
Liu B; Ordonez-Ercan D; Fan Z; Huang X; Edgerton SM; Yang X; Thor AD
Mol Cancer Res; 2009 Nov; 7(11):1882-92. PubMed ID: 19861407
[TBL] [Abstract][Full Text] [Related]
16. Trans-activating mutations of the pseudokinase ERBB3.
Koivu MKA; Chakroborty D; Airenne TT; Johnson MS; Kurppa KJ; Elenius K
Oncogene; 2024 May; ():. PubMed ID: 38806620
[TBL] [Abstract][Full Text] [Related]
17. ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.
Morrison MM; Hutchinson K; Williams MM; Stanford JC; Balko JM; Young C; Kuba MG; Sánchez V; Williams AJ; Hicks DJ; Arteaga CL; Prat A; Perou CM; Earp HS; Massarweh S; Cook RS
J Clin Invest; 2013 Oct; 123(10):4329-43. PubMed ID: 23999432
[TBL] [Abstract][Full Text] [Related]
18. Overexpression of ERBB4 JM-a CYT-1 and CYT-2 isoforms in transgenic mice reveals isoform-specific roles in mammary gland development and carcinogenesis.
Wali VB; Gilmore-Hebert M; Mamillapalli R; Haskins JW; Kurppa KJ; Elenius K; Booth CJ; Stern DF
Breast Cancer Res; 2014 Dec; 16(6):501. PubMed ID: 25516216
[TBL] [Abstract][Full Text] [Related]
19. Role of erbB3 receptors in cancer therapeutic resistance.
Lee Y; Ma J; Lyu H; Huang J; Kim A; Liu B
Acta Biochim Biophys Sin (Shanghai); 2014 Mar; 46(3):190-8. PubMed ID: 24449784
[TBL] [Abstract][Full Text] [Related]
20. Co-conserved features associated with cis regulation of ErbB tyrosine kinases.
Mirza A; Mustafa M; Talevich E; Kannan N
PLoS One; 2010 Dec; 5(12):e14310. PubMed ID: 21179209
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
